First Tracks Biotherapeutics (NASDAQ:TRAX) Given Consensus Rating of “Buy” by Analysts

Shares of First Tracks Biotherapeutics (NASDAQ:TRAX) have received a consensus rating of “Buy” from the nine research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $38.25.

A number of brokerages recently issued reports on TRAX. Piper Sandler began coverage on First Tracks Biotherapeutics in a research report on Monday, May 4th. They set an “overweight” rating and a $54.00 price objective for the company. Leerink Partners began coverage on First Tracks Biotherapeutics in a research report on Friday, April 24th. They set an “outperform” rating and a $46.00 price objective for the company. HC Wainwright began coverage on First Tracks Biotherapeutics in a research report on Tuesday, April 28th. They set a “buy” rating and a $30.00 price objective for the company. JPMorgan Chase & Co. began coverage on First Tracks Biotherapeutics in a research report on Thursday, April 23rd. They set an “overweight” rating and a $31.00 price objective for the company. Finally, UBS Group began coverage on First Tracks Biotherapeutics in a research report on Tuesday, April 21st. They set a “buy” rating and a $45.00 price objective for the company.

First Tracks Biotherapeutics Price Performance

Shares of NASDAQ:TRAX opened at $17.78 on Wednesday. The business’s 50-day simple moving average is $17.84. First Tracks Biotherapeutics has a 12-month low of $14.72 and a 12-month high of $26.80.